Livermore, July 11, 2014 – Acumen Pharmaceuticals’ Board of Directors announced the appointment of Jeffrey Ives, Ph.D., to the company’s Board of Directors. Dr. Ives’s scientific leadership experience and expertise in drug development for Alzheimer’s disease will support Acumen’s advancement as its lead drug candidate, ACU-193, a novel, first in class, humanized monoclonal antibody that selectively targets soluble amyloid-beta oligomers, which are widely recognized as a key toxin causing Alzheimer’s disease.
“We are very pleased to welcome Jeffrey to our board of directors to assist Acumen in developing our unique soluble amyloid-beta oligomer targeting immunotherapy for the benefit of patients suffering from Alzheimer’s disease” said Grant Krafft, PhD, Founder, Chairman and Chief Scientific Advisor of Acumen. “Jeffrey’s extensive expertise and experience will be of tremendous benefit to Acumen as we execute on our strategy to develop ACU-193 for Alzheimer’s patients.”
“I am delighted to join Acumen’s Board of Directors,” said Dr. Ives. “I look forward to helping Acumen advance ACU-193 for the benefit of Alzheimer’s patients. ACU-193 is a unique Aβ immunotherapy that for the first time targets soluble amyloid beta oligomers, which are widely regarded as the principal Aβ species responsible for Alzheimer’s disease.”
Dr. Ives has over 30 years of senior management and scientific leadership experience in the development of novel therapeutics, with an emphasis on drugs for central nervous system diseases. Dr. Ives is a Principal for NeuroPharma Advisors, LLC, a Boston area advisory group dedicated to assisting companies developing therapeutics for central nervous system diseases. Prior to NeuroPharma Advisors, Dr. Ives was CEO of Satori Pharmaceuticals, which was a leading company in the development of γ-secretase modulators for the treatment of Alzheimer’s disease. Before Satori, Dr. Ives held numerous senior management positions at Pfizer including Senior Vice President of Portfolio Research, Senior Vice President of Phamacokinetics, Dynamics and Metabolism, Vice President of Central Nervous System Research, and Executive Director of Central Nervous System Medicinal Chemistry. Dr. Ives earned his Ph.D. in Chemistry from Yale University and his Bachelor’s degree in Chemistry from Colgate University.